Literature DB >> 18278860

Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.

Sandra Gemma1, Giuseppe Campiani, Stefania Butini, Gagan Kukreja, Salvatore Sanna Coccone, Bhupendra P Joshi, Marco Persico, Vito Nacci, Isabella Fiorini, Ettore Novellino, Ernesto Fattorusso, Orazio Taglialatela-Scafati, Luisa Savini, Donatella Taramelli, Nicoletta Basilico, Silvia Parapini, Giulia Morace, Vanessa Yardley, Simon Croft, Massimiliano Coletta, Stefano Marini, Caterina Fattorusso.   

Abstract

We describe herein the design, synthesis, biological evaluation, and structure-activity relationship (SAR) studies of an innovative class of antimalarial agents based on a polyaromatic pharmacophore structurally related to clotrimazole and easy to synthesize by low-cost synthetic procedures. SAR studies delineated a number of structural features able to modulate the in vitro and in vivo antimalarial activity. A selected set of antimalarials was further biologically investigated and displayed low in vitro toxicity on a panel of human and murine cell lines. In vitro, the novel compounds proved to be selective for free heme, as demonstrated in the beta-hematin inhibitory activity assay, and did not show inhibitory activity against 14-alpha-lanosterol demethylase (a fungal P450 cytochrome). Compounds 2, 4e, and 4n exhibited in vivo activity against P. chabaudi after oral administration and thus represent promising antimalarial agents for further preclinical development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278860     DOI: 10.1021/jm701247k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functional.

Authors:  Gianluca Bartolommei; Francesco Tadini-Buoninsegni; Maria Rosa Moncelli; Sandra Gemma; Caterina Camodeca; Stefania Butini; Giuseppe Campiani; David Lewis; Giuseppe Inesi
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

2.  The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.

Authors:  Venée N Tubman; Pedro Mejia; Boris E Shmukler; Amy K Bei; Seth L Alper; James R Mitchell; Carlo Brugnara; Manoj T Duraisingh
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

3.  Structural modifications of quinoline-based antimalarial agents: Recent developments.

Authors:  Sandhya Bawa; Suresh Kumar; Sushma Drabu; Rajiv Kumar
Journal:  J Pharm Bioallied Sci       Date:  2010-04

Review 4.  Acridine-Based Antimalarials-From the Very First Synthetic Antimalarial to Recent Developments.

Authors:  Mélanie Fonte; Natália Tassi; Paula Gomes; Cátia Teixeira
Journal:  Molecules       Date:  2021-01-24       Impact factor: 4.411

Review 5.  Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development.

Authors:  Takuro Endo; Hitoshi Takemae; Indu Sharma; Tetsuya Furuya
Journal:  Front Cell Infect Microbiol       Date:  2021-12-24       Impact factor: 5.293

Review 6.  Recent advances in the discovery of haem-targeting drugs for malaria and schistosomiasis.

Authors:  Katherine A de Villiers; Timothy J Egan
Journal:  Molecules       Date:  2009-08-04       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.